Improvement in liver disease parameters following treatment with daclatasvir plus sofosbuvir and ribavirin in patients with chronic HCV infection and advanced cirrhosis

被引：0
|
作者：
Fontana, Robert J. [1 ]
Poordad, Fred [2 ]
Schiff, Eugene R. [3 ]
Vierling, John M. [4 ]
Landis, Charles S. [5 ]
Bhore, Rafia [6 ]
Yin, Philip [7 ]
Noviello, Stephanie [6 ]
Swenson, Eugene S. [7 ]
机构：
[1] Univ Michigan, Med Ctr, Ann Arbor, MI USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA
[3] Univ Miami, Miller Sch Med, Schiff Ctr Liver Dis, Miami, FL 33136 USA
[4] Baylor Coll Med, Houston, TX 77030 USA
[5] Univ Washington, Sch Med, Seattle, WA USA
[6] Bristol Myers Squibb Co, Princeton, NJ USA
[7] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
706
引用
收藏
页码：558A / 559A
页数：2
相关论文
共 50 条
  • [1] Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
    Charlton, Michael
    Everson, Gregory T.
    Flamm, Steven L.
    Kumar, Princy
    Landis, Charles
    Brown, Robert S., Jr.
    Fried, Michael W.
    Terrault, Norah A.
    O'Leary, Jacqueline G.
    Vargas, Hugo E.
    Kuo, Alexander
    Schiff, Eugene
    Sulkowski, Mark S.
    Gilroy, Richard
    Watt, Kymberly D.
    Brown, Kimberly
    Kwo, Paul
    Pungpapong, Surakit
    Korenblat, Kevin M.
    Muir, Andrew J.
    Teperman, Lewis
    Fontana, Robert J.
    Denning, Jill
    Arterburn, Sarah
    Dvory-Sobol, Hadas
    Brandt-Sarif, Theo
    Pang, Phillip S.
    McHutchison, John G.
    Reddy, K. Rajender
    Afdhal, Nezam
    [J]. GASTROENTEROLOGY, 2015, 149 (03) : 649 - 659
  • [2] DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR TREATMENT OF CHRONIC HCV INFECTION IN PATIENTS WITH ADVANCED LIVER DISEASE: RESULTS OF A EUROPEAN COMPASSIONATE USE PROGRAM
    Welzel, T.
    Petersen, J.
    Herzer, K.
    Ferenci, P.
    Gschwantler, M.
    Cornberg, M.
    Ingiliz, P.
    Berg, T.
    Spengler, U.
    Weiland, O.
    van der Valk, M.
    Klinker, H.
    Rockstroh, J.
    Peck-Radosavljevic, M.
    Zhao, Y.
    Jimenez-Exposito, M. J.
    Zeuzem, S.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S825 - S825
  • [3] EFFECT OF RIBAVIRIN ON THE SAFETY PROFILE OF DACLATASVIR plus SOFOSBUVIR FOR PATIENTS WITH CHRONIC HCV INFECTION
    Sulkowski, M.
    Gardiner, D.
    Hughes, E.
    Huang, S. -P.
    Grasela, D.
    [J]. JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S471 - S471
  • [4] DACLATASVIR PLUS SOFOSBUVIR PLUS RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT-EXPERIENCED PATIENTS WITH HCV GENOTYPE 3 INFECTION AND ADVANCED FIBROSIS OR CIRRHOSIS
    Hezode, C.
    Dore, G.
    Pianko, S.
    Pol, S.
    Stuart, K.
    Thompson, A.
    Tse, E.
    Bhore, R.
    Jimenez-Exposito, M. J.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S753 - S754
  • [5] Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients With HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis
    Hezode, Christophe
    Dore, Gregory J.
    Pianko, Stephen
    Pol, Stanislas
    Stuart, Katherine
    Thompson, Alexander
    Tse, Edmund
    Bhore, Rafia
    Jimenez-Exposito, Maria Jesus
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S1096 - S1096
  • [6] An integrated safety analysis of daclatasvir plus sofosbuvir, with or without ribavirin, in patients with chronic HCV infection
    Landis, Charles S.
    Nelson, David R.
    Sulkowski, Mark S.
    Ruane, Peter J.
    Mills, Anthony M.
    Poordad, Fred
    Wyles, David L.
    Bhore, Rafia
    Ackerman, Peter
    Rana, Khurram
    Swenson, Eugene S.
    Noviello, Stephanie
    [J]. HEPATOLOGY, 2015, 62 : 565A - 565A
  • [7] DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV INFECTION IN PATIENTS WITH DECOMPENSATED CIRRHOSIS: RESULTS OF A EUROPEAN MULTICENTRE COMPASSIONATE USE PROGRAM
    Petersen, J.
    Welzel, T.
    Herzer, K.
    Ferenci, P.
    Gschwantler, M.
    Cornberg, M.
    Ingiliz, P.
    Berg, T.
    Spengler, U.
    Weiland, O.
    van der Valk, M.
    Klinker, H.
    Rockstroh, J.
    Peck-Radosavljevic, M.
    Zhao, Y.
    Jimenez-Exposito, M. J.
    Zeuzem, S.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S781 - S782
  • [8] Effect of Ribavirin on the Safety Profile of Daclatasvir Plus Sofosbuvir for Patients With Chronic HCV Infection Presidential Poster
    Sulkowski, Mark
    Gardiner, David
    Hughes, Eric
    Huang, Shu-Pang
    Grasela, Dennis
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S169 - S169
  • [9] Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease
    Rockstroh, Juergen K.
    Ingiliz, Patrick
    Petersen, Joerg
    Peck-Radosavljevic, Markus
    Welzel, Tania M.
    Van der Valk, Marc
    Zhao, Yue
    Jimenez-Exposito, Maria Jesus
    Zeuzem, Stefan
    [J]. ANTIVIRAL THERAPY, 2017, 22 (03) : 225 - 236
  • [10] Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a compassionate use program
    Welzel, T.
    Herzer, K.
    Ferenci, P.
    Petersen, J.
    Gschwantler, M.
    Cornberg, M.
    Berg, T.
    Spengler, U.
    Weiland, O.
    Van der Valk, M.
    Klinker, H.
    Rockstroh, J.
    Ingiliz, P.
    Peck-Radosavljevic, M.
    Jimenez-Exposito, M. J.
    Zeuzem, S.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2015, 22 : 4 - 5
12345